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Abstract 
After a quarter of century of rapid technological advances, research has revealed the complexity of 
cancer, a disease intimately related to the dynamic transformation of the genome. However, the full 
understanding of the molecular onset of this disease is still far from achieved and the search for 
mechanisms of treatment will follow closely. 
It is here that Nanotechnology enters the fray offering a wealth of tools to diagnose and treat cancer. 
It is indisputable that the use of gold nanocarriers has been gaining momentum as vectors for therapy 
and diagnostic strategies, combining the AuNPs’ ease of functionalization with numerous 
biomolecules, high loading capacity and fast uptake by target cells. In fact, over the last decade 
nearly 12.000 research papers focusing on multifunctional gold nanocarriers have been published in 
peer-reviewed journals. Some of the described nanosystems will most likely revolutionize our 
understanding of biological mechanisms and push forward the clinical practice through their 
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integration in future diagnostics platforms. Nevertheless, very little gave fruitful results in order to 
improve a bench-to-bedside approach to translational research. On the basis of theoretical and 
experimental results obtained so far are we or not at the point: from bench to bedside and back 
again? As you will see, the answers to this question are complex, but one thing is clear: Translation 
into clinics is a tortuous and difficult path. Here, we provide a critical review about the available 
multifunctional gold nanocarriers for in vitro application and in vivo cancer targeting on 
nanodiagnostics and therapy.  
 
Keywords: cancer; gold nanoparticles; nanomedicine; theranostics; nanotoxicity. 
 
1. Introduction 
The National Cancer Institute predicts that over the next years, nanotechnology will result in 
important advances in early detection, molecular imaging, targeted and multifunctional therapeutics, 
prevention and control of cancer (2010). Nanotechnology offers numerous tools to diagnose and treat 
cancer, such as new imaging agents, multifunctional devices capable of overcome biological barriers 
to deliver therapeutic agents directly to cells and tissues involved in cancer growth and metastasis, 
and devices capable of predicting molecular changes to prevent action against precancerous cells 
(Baptista, 2009).  
Nanoparticle-based delivery systems in Theranostics (Diagnostics & Therapy) provide better 
penetration of therapeutic and diagnostic substances within the body at a reduced risk in comparison 
to conventional therapies (Ma et al., 2011;Praetorius and Mandal, 2007). Limitations in medical 
practice are intimately associated with the fact that diagnostics, therapy and therapy guidance are 
mostly separate from each other. It is here that theranostics unites the three stages in one single 
process, supporting early-stage diagnosis and treatment, overcoming some of the sensitivity and 
specificity of current medicines (Lammers et al., 2010;Pene et al., 2009;Lammers et al., 2011). At 
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the present time, there is a growing need to enhance the capability of theranostics procedures where 
nanoparticle-based sensors may provide for the simultaneous detection of several gene-associated 
conditions and nanodevices with the ability to monitor real-time drug action. These innovative 
multifunctional nanocarriers for cancer theranostics may allow the development of diagnostics 
systems such as colorimetric and immunoassays, and in therapy approaches through gene therapy, 
drug delivery and tumor targeting systems (Figure 1). 
Nowadays the main challenge is to develop a system for molecular therapy capable of circulating in 
the blood stream undetected by the immune system and capable to recognize the desirable target and 
signal it for effective drug delivery or gene silencing. As a result, nanotechnology is playing a role in 
providing new types of nanotherapeutics for cancer that have the potential to provide effective 
therapies with minimal side effects and with high specificity (Heath and Davis, 2008). The 
interdisciplinary and vibrant field of nanotechnology continues giving us hope of a personalized 
medicine as a part of cancer patient management. Gold nanoparticles (AuNPs) are one of those 
nanosystems that provide non-toxic carriers for drug and gene delivery applications (Nishiyama, 
2007;Ghosh et al., 2008a). They are versatile agents with a variety of biomedical applications 
including use in highly sensitive diagnostic assays (Goodman et al., 2004), thermal ablation and 
radiotherapy enhancement (Hirsch et al., 2003;Hainfeld et al., 2004;Hainfeld et al., 2008), as well as 
drug and gene delivery (Hong et al., 2006;Thomas and Klibanov, 2003a). 
The unique characteristics of AuNPs in the nanometer range, such as high surface-to-volume ratio or 
size-dependent optical properties, are drastically different from those of their bulk materials and hold 
pledge in the clinical field for disease therapeutics (Kim, 2007;Heath and Davis, 2008). 
Nanoparticles (NPs) exhibiting these unique and broad-based optical properties, ease of synthesis 
and facile surface chemistry and functionalization, and appropriate size scale are generating much 
eagerness in clinical diagnostics and therapy. The most common applications in which gold 
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nanocarriers have been used so far are labeling, delivering, heating, sensing and detection (Sperling 
et al., 2008). 
In spite of these advantages, nanoparticles show some limitations, such as their small size and large 
surface area can lead to particle-particle aggregation and may result in limited loading of functional 
components and burst release. In fact, only NPs with the appropriate size (and surface chemistry) 
will not be immediately recognized by our immune system and committed to removal from the 
organism, thus showing increased circulation times. Also, size and surface properties play an 
important role to avoid clearance (Sperling and Parak, 2010). For example, hydrophilic nanoparticles 
with an effective size in the range of 10 to 100 nm are small enough to slow down activation of the 
mononuclear phagocyte system and are big enough to avoid renal filtration (Gil and Parak, 2008). 
Nanoparticles with unique and broad-based optical properties, ease of synthesis and facile surface 
chemistry and functionalization, and appropriate size scale are generating much eagerness in 
biotechnology and biomedicine with particular emphasis in clinical diagnostics and therapy (Doria et 
al., 2012). However for the biological application of these multifunctional NPs, is necessary their 
functionalization with one or several biomolecules such as DNA/RNA, oligonucleotides (i.e. 
ssDNA/RNA, dsDNA/RNA ), peptides and antibodies, fluorescent dyes, polymers, drugs, tumoral 
markers, enzymes and other proteins that will introduce several functionalities and moieties. In the 
end the conjugation strategy is directly dependent of a numbers of factors, namely the NPs size, 
surface chemistry and shape, as well as the type of ligands and functional groups one desires to 
exploit in the functionalization (Sperling and Parak, 2010).  
When referring to cancer therapy, targeting and localized delivery are of utmost importance to 
enhance the therapeutic effect and decrease an adverse distribution to healthy organs and tissues. 
Multifunctional gold nanocarriers may potentiate the development of individualized cancer therapy 
based on the individual’s biological information within the tumor (i.e. biomolecular profiling). Gold 
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nanocarriers can be modified with multiple cell-targeting and membrane translocating peptides, 
loaded with DNA/RNA and used as nanovectors (Gil and Parak, 2008;Peer et al., 2007). 
In this chapter, we will focus on the exciting new methods and applications of AuNPs for cancer 
diagnosis and therapy with particular emphasis on their use in vivo and their potential to be translated 
into clinical settings.  
 
1. Nanodiagnostics 
Nanodiagnostics can be defined as the use of nano-sized materials, devices or systems for 
diagnostics purposes (Doria et al., 2007a). It is a promising field as more and improved techniques 
are becoming available for clinical diagnostics with increased sensitivity at lower costs (Baptista et 
al., 2008;Baptista et al., 2005;Doria et al., 2007b;Baptista et al., 2006).  
The use of the colloidal gold color change upon aggregation is the best characterized example for 
diagnostic systems using AuNPs.  In fact, AuNPs functionalized with ssDNA capable of specifically 
hybridizing to a complementary target for the detection of specific nucleic acid sequences in 
biological samples have been extensively used (Li and Rothberg, 2004;Mirkin et al., 1996;Thaxton et 
al., 2006;Cheng et al., 2006;Baptista et al., 2008;Doria et al., 2007b;Taton et al., 2000;Qin and Yung, 
2007;Sato et al., 2005;Sato et al., 2003;Elghanian et al., 1997).   
The use of thiol-linked ssDNA-modified gold nanoparticles for the colorimetric detection of gene 
targets represents an inexpensive and easy to perform alternative to fluorescence or radioactivity-
based assays (Storhoff et al., 2004). In 1996, Mirkin et al. (Mirkin et al., 1996) described the use of a 
cross-linking method that relies on the detection of single-stranded oligonucleotide targets using two 
different Au-nanoprobes, each of them functionalized with a DNA-oligonucleotide complementary 
to one half of the given target. A mixture of gold nanoparticles with surface-immobilized non-
complementary DNA sequences appears red in color and has a strong absorbance at 520 nm. When a 
complementary DNA sequence is added, the nanoparticles are reversibly aggregated causing a red 
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shift in the surface plasmon absorbance to 574 nm, and the solution becomes purple in color. 
Consequently, these AuNPs reversibly assemble by the formation of the DNA duplex, linking the 
particles together. These pioneer work gave the research community the idea of an easy method to 
sensitized oligonucleotide–AuNP conjugates, with intense and highly tunable optical properties, ease 
of conjugation though the gold–thiol bond, catalytic properties, and relative biocompatibility 
(Thaxton et al., 2006;Cao et al., 2005).  
On the other hand, in 2005 Baptista et al. introduced a non-cross linking method where thiol-linked 
DNA-gold nanoparticles were used in a novel colorimetric method to detect the presence of specific 
mRNA from a total RNA extract of yeast cells (Baptista et al., 2005). The method consists in visual 
and/or spectrophotometric comparison of solutions before and after salt induced Au-nanoprobe 
aggregation (see Figure 2) – the presence of a complementary target prevents aggregation and the 
solution remains red and has a strong absorbance at ±520 nm; non-complementary/mismatched 
targets do not prevent Au-nanoprobe aggregation, resulting in a visible change of color from red to 
blue and therefore a shift in the surface plasmon absorbance to 600-650 nm. This method has been 
successfully applied to detect eukaryotic gene expression without retro-transcription or PCR 
amplification steps (Conde et al., 2010b;Baptista et al., 2005); to distinguish fully complementary 
from mismatched sequences, with a single base mismatch i.e. to detect common mutations within the 
β-globin gene (Doria et al., 2007b); and in a fast and straightforward assay for Mycobacterium 
tuberculosis DNA detection in clinical samples (Costa et al., 2009;Baptista et al., 2006). 
Other approaches are the use of AuNPs as a core/seed that can be tailored with a wide variety of 
surface functionalities to provide highly selective nanoprobes for diagnosis (You et al., 2007); the 
utilization of Surface Plasmon resonance (SPR) scattering imaging or SPR absorption spectroscopy 
generated from antibody conjugated AuNPs in molecular biosensor techniques for the diagnosis and 
investigation of oral epithelial living cancer cells in vivo and in vitro (El-Sayed et al., 2005a); the use 
of multifunctional AuNPs which incorporate both cytosolic delivery and targeting moieties on the 
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same particle functioning  as intracellular sensors to monitoring actin rearrangement in live 
fibroblasts (Kumar et al., 2007); and the employment of AuNPs in electrochemical based methods 
that can be coupled with metal deposition for signal enhancement (Castaneda et al., 2007). 
Gold NPs have already proven to be one of the most important groups of nanomaterials for 
biosensing approaches. Highly sensitive and specific biosensors based on AuNPs have open up the 
possibility of creating new diagnostic platforms for disease markers, biological and infectious agents 
in the early-stage detection of disease and threats, especially in cancer (Conde et al., 2012b;Doria et 
al., 2012). 
 
1.1. Gold nanocarriers in Cancer Diagnosis  
Cancer is the one of first leading causes of mortality in the modern world, with more than 10 million 
new cases every year (Hanahan and Weinberg, 2000;Siegel et al., 2012). Some continue to argue that 
the search for the origin and treatment of this disease will continue through the next quarter of 
century, adding successive layers of complexity to an investigation that per se is very complex. In 
fact, advances in diagnosis and treating this disease that kills millions of people each year 
worldwide, have not been as effective as for other chronic diseases, and only for some types of 
cancer there are effective methods of detection (Hanahan and Weinberg, 2000). The high mortality 
rate in cancer is commonly attributed to the difficulties in detecting the disease at an early treatable 
stage. The main challenge is to find new and more effective diagnostic agents for the monitorization 
of predictive cell molecular changes that are involved in tumor development as the key to the 
efficient and ultimately triumphant treatment of cancer is early and accurate diagnosis (Etzioni et al., 
2003).  
It is here that nanotechnology enters the fight in the technological leap of controlling materials at 
nanoscale by offering a “big revolution” in new medical and healthcare diagnostic systems (Gil and 
Parak, 2008). In fact, nanotechnology combined with biology and medicine is the most advanced 
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technology both from an academic point-of-view and for commercial applications, producing major 
advances in molecular diagnostics and bioengineering (Giljohann et al., 2010;Salata, 2004). AuNPs 
are one of those nanosystems that provide non-toxic carriers with a variety of biomedical 
applications including use in highly sensitive diagnostic assays (Conde et al., 2012b;Doria et al., 
2012). 
In reality the multiplexed marker protein assays are critical in the diagnosis of complex diseases like 
cancer. In fact, AuNP probes barcoded with reporter DNAs and a capture antibody have been 
extensively used with great promise (Stoeva et al., 2006;Son and Lee, 2007). For instance, AuNP 
imunoassays are one of the most used nanosystems in cancer detection. Mirkin and co-workers 
developed an ultrasensitive method for detecting protein analytes. This facile immunoassay was used 
for the detection of prostate specific antigen (PSA, a valuable biomarker for prostate cancer 
screening) and had an almost one million-fold higher sensitivity than a conventional ELISA-based 
assay (Nam et al., 2003). This study was the first step to use six years later the AuNP bio-barcode 
assay probe for the detection of PSA in a clinical pilot study with 18 men who have undergone 
radical prostatectomy for prostate cancer. This new bio-barcode PSA assay is approximately 300 
times more sensitive than commercial immunoassays (Thaxton et al., 2009).  
Also, Huang et al. have reported a PSA immunoassay on a commercially available surface plasmon 
resonance biosensor. This sandwich assay with AuNPs was used for a major enhancement in 
sensitivity of PSA detection at clinical relevant concentrations (Huang et al., 2005). Other study 
demonstrated a highly sensitive organic electrochemical transistor based immunosensor with 
secondary antibody-conjugated AuNPs with a low detection limit for PSA. These sensor 
performances were particularly improved in the lower concentration range where the detection is 
clinically important for the preoperative diagnosis and screening of prostate cancer (Huang et al., 
2005). 
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Additionally, AuNP probes coupled with dynamic light scattering (DLS) measurements can also be 
used for the development of a one-step homogeneous immunoassay for the detection of free-PSA. 
The light scattering intensity of nanoparticles and nanoparticle oligomers is several orders of 
magnitude higher than proteins, making it possible to detect nanoparticle probes in the low 
picomolar concentration range (Liu et al., 2008). 
AuNPs scatter light intensely at or near their surface plasmon wavelength region and when coupled 
with DLS detection can be very useful for serum protein biomarker detection and analysis. Huo et al. 
reported the use of citrate-AuNP to absorb proteins from the serum and form a protein corona on the 
nanoparticle surface. The protein corona formation and the subsequent binding of antibody to the 
target proteins in the protein corona were detected by DLS. Using this simple assay, the authors 
discovered multiple molecular aberrations associated with prostate cancer from both mice and human 
blood serum samples (Huo et al., 2012;Huo et al., 2011). 
Other authors have taken a different approach to addressing the use of AuNPs in cancer biomarker 
detection by employing the biological applications of antibody-conjugated AuNPs in several types of 
cancer, such as breast cancer (Ambrosi et al., 2010;Lu et al., 2010a), pancreatic adenocarcinoma 
(Eck et al., 2008), cervical cancer (Rahman et al., 2005), epithelial cancer (Yang et al., 2008), liver 
cancer (Lan et al., 2011), prostate cancer (Lukianova-Hleb et al., 2011) and oral cancer (El-Sayed et 
al., 2005a). 
The mechanism of selectivity and all these immunoassay's response open up a new possibility of 
rapid, simple, clean, easy, economically very cheap, non-toxic and reliable diagnosis of cancer. In 
fact, antibody-conjugated AuNPs are one of the most used nanosystems in cancer diagnostics, being 
useful in molecular biosensor techniques for the diagnosis and investigation of cancer cells in vivo 
and in vitro. The importance of these nanosystems can be demonstrated by a significant number of 
companies involved in the synthesis and applications of antibody-conjugated nanoparticles, such as 
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Magnisense SAS, Diagnostic Biosensors, LLC, Alnis Biosciences Inc. and Invitrogen Corp (Arruebo 
et al., 2009). 
Direct detection of cancer cells using colorimetric assays with AuNPs has been extensively used due 
to their simplicity and versatility, among which those based on LSPR. LSPR is the collective 
oscillation of the electrons in the conduction band, which is usually in the visible region giving rise 
to the strong surface plasmon resonance absorption (Daniel and Astruc, 2004). These AuNPs are 
commonly functionalized with biomolecules (e.g., DNA, RNA, peptides, enzymes) and capable of 
recognizing molecular events associated with cancer development down to femtomolar level with 
single base discrimination resolution (Kang et al., 2010;Li et al., 2005;Medley et al., 2008). 
Molecular nanodiagnostics applied to cancer may provide rapid and sensitive detection of cancer 
related molecular alterations, which would enable early detection even when those alterations occur 
only in a small percentage of cells. For instance, Conde et al. present an AuNPs based approach for 
the molecular recognition and quantification of the BCR-ABL fusion transcript, which is responsible 
for chronic myeloid leukemia (CML). This inexpensive and very easy to perform method allows 
quantification of unamplified total human RNA and specific detection of the oncogene transcript. 
This assay may constitute a promising tool in early diagnosis of CML and could easily be extended 
to further target genes with proven involvement in cancer development (Conde et al., 2010b;Conde 
et al., 2012c). The sensitivity settled by the Au-nanoprobes allows differential gene expression from 
10 ng/μl of total RNA and takes less than 30 minutes to complete after total RNA extraction, 
minimizing RNA degradation (see Figure 2).  
Also, aptamer-conjugated AuNPs have become a powerful tool for point of care diagnostics 
(Mukerjee et al., 2012). Most of the common aptamer-AuNP assays are able to differentiate between 
different types of target and control cells based on the aptamer used in the assay, indicating the wide 
applicability for cancer cell detection. For instance, Liu et al. reported the use of an aptamer-
nanoparticle strip biosensor for the rapid, specific, sensitive, and low-cost detection of circulating 
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cancer cells in human blood, showing great promise for in-field and point-of-care cancer diagnosis 
and therapy (Liu et al., 2009). In another study, Medley et al. have developed a colorimetric assay for 
the direct detection of diseased cells and thus capable of distinguish between cancer cells and 
noncancerous cells. This assay combines the selectivity and affinity of aptamers and the 
spectroscopic advantages of AuNPs to allow for the sensitive detection of cancer cells with both the 
naked eye and based on absorbance measurements (Medley et al., 2008). Another important aspect 
correlated with disease state in cancer patients is the presence of circulating tumor cells in the 
bloodstream. In order to induce optical contrast in non-pigmented cancer cells, Viator et al. attached 
AuNPs to a prostate cancer cell line, using optical absorption to detect such cells in a photoacoustic 
flowmeter designed to find circulating tumor cells in blood samples (Viator et al., 2010).  
Another application of AuNPs in cancer is their capability to target and provide in vivo tumor 
detection using Surface-enhanced Raman scattering - SERS. SERS has led the way in terms of use of 
spectroscopic methods for signal enhancement by nanostructured metal surfaces towards in vivo 
tracking of biomolecules trafficking (Stiles et al., 2008;Wilson and Willets, 2013). SERS has been 
extensively used for molecular/ion detection and bioimaging applications since it minimizes 
photoblinking or photobleaching from conventional fluorophores, decreases signal-to-noise ratio in 
complex in vitro and in vivo, and usually Raman reporters are stable and yield large optical 
enhancements (Alvarez-Puebla and Liz-Marzan, 2010;Samanta et al., 2011;Alvarez-Puebla and Liz-
Marzan, 2012b;Alvarez-Puebla and Liz-Marzan, 2012a). AuNPs covered by Raman reporters have 
been used for SERS to detect cancer cells in vitro and tumours in vivo (Kong et al., 2012;Qian et al., 
2008b). Actually, Lin et al. described the tremendous potential of using AuNP based-SERS to obtain 
blood serum biochemical information for non-invasive colorectal cancer detection (Lin et al., 2011). 
Raman reporters when combined with AuNPs can elicit an optical contrast to discriminate between 
cancerous and normal cells and their conjugation with antibodies allowed them to map the 
expression of relevant biomarkers for molecular imaging (Kah et al., 2007), ], as well as detect and 
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characterized circulating tumor cells. These SERS nanoparticles constitute an important tool for 
clinical research once they can successfully identified circulating tumor cells in the peripheral blood 
of 19 patients with squamous cell carcinoma of the head and neck (Wang et al., 2011). 
The papers discussed earlier report the development of nanoscale devices and platforms that can be 
used for improved biomarker detection, such as nucleic acids (DNA or RNA) or proteins. However, 
the development of molecular diagnosis of cancer and at the same time the selective delivery of a 
specific anticancer agent by joining diagnostics and therapy (theranostics) on a single nanodevice 
will most definitely revolutionizing the way we manage cancer (Baptista, 2012). 
Table 1 summarizes the latest types of AuNP-based biosensors for cancer dignostics, according to 
their methodology principle. Some of the described nanosystems will most likely revolutionize our 
understanding of biological mechanisms and push forward the clinical practice through their 
integration in future diagnostics platforms. Nevertheless, very little gave successful results or went to 
clinical trials. Therefore new synthesis, fabrication, and characterization methods are needed for 
developing highly advanced AuNPs capable of use in sensitive and multiple detection methods with 
negligible toxicity and high sensitivity. In the future, it might be possible to apply all AuNPs 
properties together and evolve new chemistry for synthesis of smart materials for diagnostic 
applications and clinical trials. 
 
Table 1. Summary of the latest AuNP-based biosensors used in cancer diagnostics according to the 
type of NP, surface modification, type of cancer and explored methodology principle. 
Method 
Type 
of NP 
Surface 
modification 
Target/Cells/ 
Samples 
Type of 
Cancer 
Comments 
[Reference] 
Colorimetric 
 
Scanometric 
40 nm 
spherical 
dA-tailed probe 
applied to the strip, 
which contains 
oligo(dT)-
conjugated AuNPs 
in dry form 
Fusion genes in 
K562 cell line 
acute and 
chronic 
leukemia 
Dry-reagent, disposable, 
dipstick test for molecular 
screening of seven 
chromosomal translocations 
associated with acute and 
chronic leukemia 
(Kalogianni et al., 2007) 
13 nm 
spherical 
ssDNA 
BCR-ABL b3a2 
(e14a2) fusion 
Chronic 
myeloid 
Detection and quantification 
of the 
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transcript leukemia BCR-ABL gene fusion using 
thiol-DNA modified AuNPs 
(Conde et al., 2010b) 
30 nm 
spherical 
thiol-terminated 
DNA barcodes; 
anti-PSA antibodies 
Prostate-specific 
antigen PSA 
(biomarker for 
prostate cancer 
screening) 
Prostate cancer 
Nanoparticle based bio-
barcode for PSA detection 
(Thaxton et al., 2009) 
15 nm 
spherical 
antibody anti-
CA15-3−HRP 
(horseradish 
peroxidase) 
CA15-3 breast 
cancer biomarker 
in human serum 
Breast cancer 
Enhanced AuNP based 
ELISA for a breast cancer 
biomarker detection 
(Ambrosi et al., 2010) 
oval-
shaped 
monoclonal anti-
HER2/c-erb-2 
antibody; S6 RNA 
aptamer-conjugated 
SK-BR-3 cells Breast cancer 
Colorimetric and highly 
sensitive two-photon 
scattering assay for highly 
selective and sensitive 
detection of breast cancer 
(Lu et al., 2010a) 
Immunoassays 
15 nm 
spherical 
dithiol-PEG-
COOH; F19 
monoclonal 
antibodies 
Tissues from 
cancerous and 
healthy human 
pancreas (patients 
undergoing 
pancreatic 
resection) 
Pancreatic 
adenocarcinoma 
pancreatic adenocarcinoma 
(Eck et al., 2008) 
25 nm 
spherical 
anti-EGFR and 
non-specific IgG 
antibodies 
SiHa cervical 
cancer cells 
Cervical cancer 
Optical imaging of cervical 
pre-cancers using AuNPs 
and CdSe QDs for 
reflectance and fluorescence 
imaging (Rahman et al., 
2005) 
10 nm 
spherical 
antibody 
(Cetuximab) 
epidermal growth 
factor receptor 
(EGFR) in A431 
cells 
Liver cancer 
High-performance probes 
based on AuNPs for 
detection of live cancer cell 
(Yang et al., 2008) 
16 nm 
spherical 
NHS-PEG; mouse 
anti-human AFP 
antibodies 
(antibody-1 and 
antibody-2) 
liver cancer 
biomarker alpha-
fetoprotein (AFP) 
Liver cancer 
One-step homogeneous 
detection of cancer marker 
using antibody-AuNP probes 
(Lan et al., 2011) 
60 nm 
spherical 
PSMA (prostate 
specific membrane 
antigen); C225 
(Erbitux, the 
antibody raised 
against human EGF 
receptor) 
living bone 
metastatic prostate 
cancer (C4-2B); 
human bone 
marrow stromal 
(HS-5) cells 
Prostate cancer 
Tunable plasmonic 
nanoprobes for theranostics 
of prostate Cancer 
(Lukianova-Hleb et al., 
2011) 
35 nm 
spherical 
monoclonal anti-
epidermal growth 
factor receptor 
(anti-EGFR) 
nonmalignant 
epithelial cells 
(HaCaT); 
malignant oral 
epithelial cells 
(HOC 313 clone 8 
and HSC 3) 
Oral cancer 
Surface plasmon resonance 
scattering and absorption of 
antibody-AuNPs in oral 
cancer diagnostics (El-Sayed 
et al., 2005a) 
Surface-
enhanced 
Raman 
scattering - 
SERS 
30 nm 
spherical 
mouse anti-human 
free PSA clone 
PSA-F65 and clone 
PSA-66 
Prostate-specific 
antigen (PSA) in 
human serum 
Prostate cancer 
Detection of PSA with an 
immunoassay based on 
SERS and immunogold 
labels (Grubisha et al., 2003) 
43 nm 
spherical 
human serum human serum 
Colorectal 
cancer 
AuNP based-SERS to obtain 
blood serum biochemical 
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information for non-invasive 
colorectal cancer detection 
(Lin et al., 2011) 
60 nm 
spherical 
QSY reporter 
molecules; thiol-
PEG-COOH; 
epidermal growth 
factor (EGF) 
peptide 
epidermal growth 
factor (EGF) 
Squamous cell 
carcinoma of 
the head and 
neck 
SERS AuNPs identified 
circulating tumor cells in the 
peripheral blood of cancer 
patients (Wang et al., 2011). 
35-50 nm 
spherical 
Thiol-DNA hairpin 
tagged with a 
Raman label 
BRCA1 SNPs Breast cancer 
Plasmonic 
nanoprobes for detection of 
SNPs in breast cancer 
BRCA1 gene (Wabuyele et 
al., 2010) 
Electrochemical 
5 nm 
spherical 
Glutathione (GSH); 
primary antibodies 
for human 
Interleukin-8 
Interleukin-8 (IL-8) 
cancer biomarker 
in human serum 
Cancer 
biomarker 
Ultrasensitive 
immunosensor based on a 
glutathione-protected 
AuNP sensor surface 
(Munge et al., 2011) 
4 nm 
spherical 
antibodies for IL-6; 
biotinylated 
secondary antibody 
with 16-18 
horseradish 
peroxidase labels 
Interleukin-6 (IL-6) 
cancer biomarker 
in calf serum 
Cancer 
biomarker 
Inkjet printed AuNP 
electrochemical arrays for 
immunodetection of a cancer 
biomarker protein (Jensen et 
al., 2011) 
13 nm 
spherical 
Alkaline 
phosphatase; poly 
(styrene-co-acrylic 
acid); TNF-α 
antibody 
Tumor necrosis 
factor α (TNF-α) in 
human serum 
Tumor necrosis 
factor 
Electrochemical 
immunosensor of tumor 
necrosis factor based on 
alkaline phosphatase 
functionalized NPs (Yin et 
al., 2011) 
 
 
2. Nanotherapy 
In medical terms, a therapeutic effect is a consequence of a medical treatment of any kind, the results 
of which are judged to be desirable and beneficial. Conventional therapy methods in cancer involve 
the employment of anticancer agents that do not greatly differentiate between cancerous and normal 
cells (Minelli et al., 2010). Efficient in vivo targeting to heterogeneous population of cancer cells and 
tissue still requires better selectivity and decreased toxicity to surrounding normal cells, towards a 
decrease of systemic toxicity, adverse and severe side effects (Liu et al., 2007).  
In another way, universally targeting cells within a tumor is not always feasible because some drugs 
cannot diffuse efficiently and the random nature of the approach makes it difficult to control the 
process and may induce multiple-drug resistance (MDR)  a situation where chemotherapy 
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treatments fail patients owing to resistance of cancer cells towards one or more drugs (Peer et al., 
2007). Consequently, nanotechnology could offer a less invasive alternative, enhancing the life 
expectancy and quality of life of the patient (Cuenca et al., 2006). 
At the moment, it is expected that the greatest gains in therapeutic selectivity will be achieved by 
synergistic combinations of several multicomponent targeting strategies. Currently, it is essential to 
develop technology for target and delivery of multiple therapeutic agents, and for the simultaneous 
capability of avoiding biological and biophysiscal barriers. For example, nanoparticles can 
extravasate into the tumor stroma through the fenestrations of the angiogenic vasculature, 
demonstrating targeting by enhanced permeation and retention. These particles are able to carry 
multiple antibodies, which further target them to epitopes on cancer cells, and direct antitumor 
action, leading to cell death. Irradiation might be use to activate the nanoparticles and set up the 
release of their cytotoxic action (Ferrari, 2005). 
Due to advances in nanobiotechnology, potential therapeutic application of gold nanocarriers 
represent are an attractive platform for cancer therapy and has been investigated by different 
coworkers and used in a broad range of applications (Cuenca et al., 2006). Table 2 summarizes the 
latest progresses and general considerations for AuNP delivery and targeting in cancer therapy, 
according to their methodology principle, type of incubation/exposure and target organs. In this 
panorama we can see that over the last 10 years, the majority (approximately 80%) of gold 
nanoformulations for gene therapy, tumor targeting and drug delivery in cancer have been tested in 
cell cultures and normally targeting reporter genes, such as luciferase or GFP. In the future, it is 
imperative to develop new therapy vehicles and extensive testing in animal models in order to 
develop the next-generation nanoparticle translation into the clinics. There is only one active clinical 
trial reporting the use of AuNPs. This phase I trial is studying the side effects and best dose of TNF-
bound colloidal gold in treating patients with advanced solid tumors (clinical trial number 
NCT00356980), sponsored by the National Institutes of Health Clinical Center (CC) and National 
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Cancer Institute (NCI). As it can be seen in Figure 3 there is a disproportional level between 
nanoparticle production and their translation into clinics.  
In fact, clinical trials require the coordinated effort of interdisciplinary research groups, institutes and 
pharmaceuticals. Clinical-stage programs will probably have to deal with more and more human data 
and financial investment, before they can be viewed as a mainstream proposition for resourceful 
nanotherapy vehicle developers. The current generation of nanoparticles varies widely in size, 
chemical composition, surface charge, tissue tropism and sensitivity that makes difficult to translate 
them into the manufacturing process. The community has to learn how to deal with all the dat 
produced so far. The rules for understanding how nanoparticles interact with different organs and 
organisms are starting to emerge, although most of the valuable evidences have to come from animal 
models. 
 
Table 2. Summary of AuNPs used in cancer therapy according to the type of NP, surface 
modification, type of cancer, target cells/organs/organisms and explored methodology principle. 
Method 
Type of 
AuNP 
Surface modification 
Target 
cells/organs/organisms 
Comments [Reference] 
Gene 
therapy 
13 nm 
spherical 
thiol-ssDNA 
RAW 264.7 
(macrophage); HeLa cells 
(cervical carcinoma); NIH-
3T3 (fibroblast); MDCK 
cells (kidney) 
In vitro intracellular gene 
Regulation; control of protein 
expression in cells (Rosi et al., 
2006) 
13 nm 
spherical 
PEG-block-poly(2-(N,N-
dimethylamino)ethyl 
methacrylate) copolymer 
(PEG-PAMA); siRNA 
HuH-7 cells 
(hepatocarcinoma) 
Smart PEGylated AuNPs for 
the in vitro delivery of siRNA 
and to induce gene silencing 
(Oishi et al., 2006) 
13 nm 
spherical 
thiol-siRNA 
HeLa cells (cervical 
carcinoma) 
Polyvalent RNA-nanoparticle 
conjugates for in vitro luciferase 
knockdown (Giljohann et al., 
2009) 
14 nm 
spherical 
thiol-siRNA; naked 
siRNA; PEG-COOH; PEG-
N3; HIV-derived TAT 
peptide; RGD peptide; 
quaternary ammonium. 
HeLa cells (cervical 
carcinoma); (freshwater 
polyp, Hydra); mice 
(C57BL/6j) 
In vitro and in vivo RNAi 
triggering using hierarchical 
approach with three 
biological systems of increasing 
complexity (Conde et al., 2012a) 
15 nm 
spherical 
cationic polymers: PEI; 
charge-reversal 
PAH-Cit; MUA 
(mercaptoundecanoic acid) 
HeLa cells (cervical 
carcinoma) 
Charge-reversal functional 
AuNPs to deliver siRNA and 
plasmid DNA into cancer cells 
(in vitro) (Guo et al., 2010) 
14 nm 
spherical 
Cy3 labeled hairpin-DNA 
HCT-116 cells (carcinoma 
of colon) 
Au-nanobeacons capable of 
intersecting both pathways of in 
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vitro RNA interference, blocking 
exogenous siRNA and 
endogenous microRNA (Conde 
et al., 2013b) 
13 nm 
spherical 
PEG-NH2; siRNA; poly(β-
amino 
ester)s (PBAEs) 
HeLa cells (cervical 
carcinoma) 
gold, Poly(β-amino ester) 
nanoparticles that facilitate 
high levels of in vitro siRNA 
delivery (Lee et al., 2009) 
40 nm 
spherical 
Protease-degradable poly-
L-lysine (PLL); siRNA 
MDA-MB231-luc cells 
(breast cancer; LNCaP-luc 
cells (prostate 
adenocarcinoma) 
multilayer siRNA coated AuNPs 
using siRNA and PLL as the 
charged polyelectrolytes for in 
vitro luciferase knockdown (Lee 
et al., 2011) 
Au-
nanospheres 
Folate receptor; siRNA 
nude mice bearing HeLa 
cervical cancer xenografts 
near-IR light-inducible NF-
kappaB in vivo downregulation 
through folate receptor-targeted 
hollow Au-nanospheres carrying 
siRNA recognizing NF-kappaB 
p65 subunit (Lu et al., 2010b) 
40 nm Au-
nanoshells 
PEG-NH2; TAT-lipid; 
Cy3-siRNA 
mouse endothelial cells 
NIR laser-induced release of 
siRNA from the nanoshells and 
in vitro GFP silencing (Braun et 
al., 2009) 
spherical 
nucleic acid 
NP 
siRNA 
HeLa cells (cervical 
carcinoma); SKH-1E and 
C57BL/6J mice 
In vitro and in vivo topical 
delivery of siRNA-based 
spherical nucleic acid AuNP 
conjugates for gene regulation 
(Zheng et al., 2012) 
Tumor 
targeting 
spherical 
pH Low Insertion Peptide 
(pHLIP) 
Mouse model 
nanogold-pHLIP conjugates used 
in vivo to target tumors (Yao et 
al., 2013) 
6 nm 
spherical 
amine-terminated 
generation 5 (G5) 
poly(amidoamine) 
(PAMAM) dendrimers pre-
functionalized with folic 
acid (FA) and fluorescein 
isothiocyanate (FI) 
KB-HFAR cells (human 
epithelial carcinoma) 
multifunctional dendrimer-
stabilized AuNPs can 
specifically target cancer cells 
expressing high-affinity FA 
receptors in vitro (Shi et al., 
2009) 
30 nm 
spherical 
PEGylated trastuzumab 
(Herceptin) 
MDA-MB-361 (breast 
cancer) tumors 
Human Epidermal Growth 
Factor Receptor-2 (HER-2)-
targeted AuNPs that enhance the 
radiation response of in vitro 
breast cancer cells and in vivo 
tumor xenografts to X-radiation 
(Chattopadhyay et al., 2013) 
4 nm 
spherical 
VEGF antibody (AbVF) 
CLL B cells (B-Chronic 
Lymphocytic Leukemia) 
AuNPs enhance in vitro 
apoptosis in B-chronic 
lymphocytic leukemia 
(Mukherjee et al., 2007) 
60 nm 
spherical 
PEG-COOH; malachite 
green isothiocyanate 
(MGITC); ScFv B10 
(antibody fragment for 
human EGFR) 
Tu686 and H520 cells 
(EGFR-positive cancer 
cells); nude mouse 
xenografted with Tu686 
cells 
Pegylated SERS AuNPs for in 
vitro and in vivo tumor targeting 
and detection (Qian et al., 2008a) 
Ultra-small 
Au-
nanoclusters 
folic acid (FA); near-
infrared fluorescent dye 
(MPA); Doxorubicin 
(DOX) 
A549 cells (lung cancer); 
HepG-2 (liver cancer); 
MDA-MB-231 (breast 
cancer); HTC116 
(carcinoma of colon) 
Cellular and in vivo studies with 
Au-FA-MPA and Au-FA-DOX 
show high affinity and anti-
tumor activity to different tumors 
(Chen et al., 2012) 
30 nm PEGylated trastuzumab MDA-MB-361 cells (breast AuNPs that enhance tumor 
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spherical (FDA-approved 
humanized monoclonal 
antibody); radiolabeled 
polymer 
cancer); athymic CD-1 mice 
bearing MDA-MB-
361tumors 
uptake and intracellular delivery 
(in vitro and in vivo) while 
reducing the systemic exposure 
by evaluation of the impact of 
targeting and route of 
administration on organ 
distribution (Chattopadhyay et 
al., 2012) 
Drug 
delivery 
2.5 nm 
spherical 
hydrophobic drugs: 
tamoxifen (TAF) 
and β-lapachone (LAP); 
Bodipy (fluorescent probe) 
MCF-7 cells (breast cancer) 
Entrapment of hydrophobic 
drugs in AuNP monolayers with 
efficient in vitro release into 
cancer cells (Kim et al., 2009a) 
30 nm 
spherical 
prostate-specific membrane 
antigen (PSMA) RNA 
aptamer; Doxorubicin 
(DOX) 
LNCaP cells (prostate 
adenocarcinoma) 
A drug-loaded aptamer−AuNP 
bioconjugate for in vitro imaging 
and therapy of prostate cancer 
(Kim et al., 2010) 
25 nm 
spherical 
thiol-PEGylated; 
tamoxifen (TAM) 
MDA-MB-361 cells (breast 
cancer); MCF-7 cells (breast 
cancer) 
Tamoxifen−poly(ethylene 
glycol)−thiol AuNPs that 
enhance potency and selective 
delivery for in vitro breast cancer 
treatment (Dreaden et al., 2009) 
180 nm 
spherical 
PEG; Oxaliplatin 
A549 cells (lung epithelial 
cancer); HCT116, HCT15, 
HT29, RKO cells (all for 
colon cancer) 
AuNPs for the improved 
anticancer drug delivery in vitro 
of the active component of 
oxaliplatin (Brown et al., 2010) 
13 nm 
spherical 
cisplatin 
A549 cells (lung cancer); 
tumor-bearing SCID mice 
In vitro and in vivo antitumoral 
drugs conjugated to AuNPs 
(Comenge et al., 2012) 
spherical Cyclic peptide 
CCRF-CEM cells (human 
leukemic lymphoblasts); 
SK-OV-3 cells (human 
ovarian adenocarcinoma) 
Cyclic peptide-capped AuNPs 
for in vitro drug delivery 
(Nasrolahi et al., 2012) 
40 nm Au-
nanospheres 
NH2-PEG-COOH; 
Doxorubicin (DOX); 
Cyclic peptide c(TNYL-
RAW), a second-
generation EphB4-binding 
antagonist 
mice bearing Hey tumors 
In vivo photothermal 
chemotherapy using 
doxorubicin-loaded Au-
nanospheres that target EphB4 
receptors in tumors (You et al., 
2012) 
plasmonic 
vesicles 
assembled 
from 14 nm 
spherical 
AuNPs 
Raman reporter; PEG;  
hydrophobic copolymer 
(PMMAVP) of methyl 
methacrylate (MMA) and 
4-vinylpyridine (4VP) 
SKBR-3 cells (breast 
adenocarcinoma) 
Self-assembled plasmonic 
vesicles of SERS-encoded 
amphiphilic AuNPs for in vitro 
cancer cell targeting and 
traceable intracellular drug 
delivery (Song et al., 2012) 
 
 
2.1 Gene therapy 
We are in the dawn of a new age in gene therapy driven by nanotechnology vehicles. Although there 
are technical challenges associated with the therapeutic application of nanoparticles, the integration 
of therapy with diagnostic profiling has accelerated the pace of discovery of new nanotechnology 
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methods. The development of a safe, efficient, specific and nonpathogenic vehicle for gene delivery 
is highly attractive (Akhtar and Benter, 2007;Kim et al., 2009b).  
Gene therapy is receiving increasing attention and, in particular, small-interference RNA (siRNA) 
shows importance in novel molecular approaches in the knockdown of specific gene expression in 
cancerous cells. In fact, this non-viral-vector-mediated delivery of therapeutic siRNAs is highly 
desirable and constitutes an important challenge to gene therapy (Castanotto and Rossi, 2009;Li et 
al., 2002;Soutschek et al., 2004).   
In fact, antisense DNA (Fichou and Ferec, 2006;Toub et al., 2006) and RNA interference (RNAi) via 
the use of small-interfering RNA (Fire et al., 1998;Baker, 2010;Milhavet et al., 2003;Wall and Shi, 
2003) have emerged as powerful and useful tools to block gene function and for sequence-specific 
posttranscriptional gene silencing, playing an important role in downregulation of specific gene 
expression in cancer cells. Thus, one drawback of using naked siRNAs is that they show extremely 
short half-lives, weak protection against action by RNases, poor chemical stability, and common 
dissociation from vector (Hannon and Rossi, 2004). In fact, the major obstacle to clinical application 
is the uncertainty about how to deliver therapeutic RNAs (e.g., miRNA and/or siRNA) with maximal 
therapeutic impact. AuNPs have shown potential as intracellular delivery vehicles for antisense 
oligonucleotides (e.g., miRNA and/or siRNA) with maximal therapeutic impact. AuNPs have shown 
potential as intracellular delivery vehicles for antisense oligonucleotides (Rosi et al., 2006) and for 
therapeutic siRNA by providing protection against RNAses and ease of functionalization for 
selective targeting (Giljohann et al., 2009;Whitehead et al., 2009). For example, Mirkin and 
coworkers reported the use of polyvalent RNA-AuNP conjugates that are readily taken up by cells 
and that the particle bound siRNA can effectively regulate genes in the context of RNA interference 
(Giljohann et al., 2009).  
Several other studies using engineered NPs modified with siRNA have demonstrated a cytoplasmic 
delivery system of siRNA and efficient gene silencing using AuNPs (Giljohann et al., 2009;Lee et 
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al., 2009;Guo et al., 2010;Lee et al., 2008). However, almost all nanoconjugates using siRNA have 
exclusively been tested in cell cultures targeting only reporter genes. 
Recently, Conde et al. provided evidence of in vitro and in vivo RNAi triggering via the synthesis of 
a library of novel multifunctional AuNPs, using a hierarchical approach including three biological 
systems of increasing complexity: in vitro cultured human cells, in vivo freshwater polyp (Hydra 
vulgaris), and in vivo mice models (Conde et al., 2012a). The authors developed effective 
conjugation strategies to combine, in a highly controlled way, specific biomolecules to the surface of 
AuNPs such as: (a) biofunctional spacers: Poly(ethylene glycol) (PEG) spacers used to increase 
solubility and biocompatibility; (b) cell penetrating peptides such as TAT and RGD peptides: A 
novel class of membrane translocating agents named cell penetrating peptides (CPPs) that exploit 
more than one mechanism of endocytosis to overcome the lipophilic barrier of the cellular 
membranes and deliver large molecules and even small particles inside the cell for their biological 
actions; and (c) siRNA complementary to a master regulator gene, the protooncogene c-myc, were 
bond covalently (SH-siRNA) and ionically (naked/unmodified siRNA) to AuNPs (Conde et al., 
2012a). 
However, efforts to target siRNA-nanoparticles to organs are less advanced. Some organs need 
smaller and novel NPs to access different kinds of tissue. Another challenge, which also requires 
novel materials, is the endosomal release of siRNA, once it is transported across the cell membrane. 
Most of the described systems also get trapped by the the lysosomes and their siRNA cargo gets 
compromised. Probably the endosomal escape or siRNA accessibility to form the RNA-induced 
silencing complex (RISC) requires substantially more circulation time. 
While the AuNPs for gene therapy discussed thus far employ the load of siRNA to nanoparticles, 
AuNPs have also shown potential as intracellular delivery vehicles for antisense oligonucleotides 
(ssDNA,dsDNA) by providing protection against intracellular nucleases and ease of 
functionalization for selective targeting (Whitehead et al., 2009;Giljohann et al., 2009). So far, 
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several strategies for gene delivery systems have been developed, including mixed monolayer 
protected AuNPs (Rana et al., 2012;Ghosh et al., 2008b), polymer-AuNPs complexes (Thomas and 
Klibanov, 2003b;Ghosh et al., 2008c) and dsDNA and ssDNA functionalized AuNPs (Conde et al., 
2010a;McIntosh et al., 2001). 
Recently, Conde et al developed a new theranostic system capable of intersecting all RNA pathways: 
from gene specific downregulation to silencing the silencers, i.e. siRNA and miRNA pathways. The 
authors reported the development AuNPs functionalized with a fluorophore labeled hairpin-DNA, 
i.e. Gold nanobeacons, capable of efficiently silencing single gene expression, exogenous siRNA and 
endogenous miRNAs while yielding a quantifiable fluorescence signal directly proportional to the 
level of silencing (Conde et al., 2013b).  
From a synthetic point of view it is still unclear the differences between DNA–AuNPs and siRNA–
AuNPs. From the papers reported so far the siRNA and DNA gold nanoconjuates are almost from 
the same size and charge, and show similar efficiencies. Nevertheless siRNA–AuNP conjugates 
require functionalization with thiol-PEG molecules to achieve equivalent stability to DNA–AuNPs, 
which may have something to do with the capacity loading of the different molecules due to singular 
hydrophobicity and/or hydrophilicity, molecular weight and charge density properties between RNA 
and DNA (Gary et al., 2007). However, this fact needs additional clarification.  
Further research into the fundamental mechanisms of in vivo gene therapy using nanodevices could 
unveil new dimensions of nanoparticle-mediated gene silencing that will have profound implications 
for understanding gene regulation, and which could also affect the development of functional 
genomics and therapeutic applications. One of the most important issues that is still unclear is how 
biocompatible AuNPs will be following intraveneous injection, in particular when the ultimate 
destination is the cytoplasm and/or nucleus inside cells. Future in vivo work will need to cautiously 
consider the accurate option of chemical modifications to incorporate into the nanoparticles to avoid 
off-target effects. Though nanoparticles’ potential against cancer is still in need of further 
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optimization and characterization, it is now time to start translating these promising platforms to the 
clinical settings towards widespread effective therapy strategies in the fight against cancer. 
 
2.2. Tumor targeting 
Nanoparticles are excellent tumor-targeting vehicles because of a unique inherent property of solid 
tumors. Numerous tumors present with defective vasculature and poor lymphatic drainage, due to the 
rapid growth of solid tumors, resulting in an enhanced permeability and retention effect. This effect 
allows nanoparticles to accumulate specifically at the tumor site (Minelli et al., 2010;Gil and Parak, 
2008). Once the tumor is directly connected to the main blood circulation system, multifunctional 
nanocarriers can exploit several characteristics of the newly formed vasculature and efficiently target 
tumors. Tumor cells are supplied by blood capillaries that perfuse the cells of the tissue where 
nanocarriers can passively accumulate or anchor through targeting moieties to biomarkers 
overexpress by tumor cells  (Conde et al., 2012b). 
Shi et al. developed a simple system with multifunctional amine terminated poly(amidoamine) 
(PAMAM) dendrimers, folic acid (FA) and fluorescein isothiocyanate functionalized in gold 
nanoparticles. This approach can specifically target cancer cells expressing high-affinity FA 
receptors in vitro (Shi et al., 2009). 
Further work in tumor targeting was reported in a subcutaneous model of colon cancer, where it was 
demonstrated that systemically delivered AuNPs (size, approximately 33 nm) conjugated to tumor 
necrosis factor (TNF) accumulated in tumors (Paciotti et al., 2004). This study outlines the 
development of a colloidal gold nanoparticle vector that targets the delivery of tumor necrosis factor 
(TNF) to a solid tumor growing in mice. 
Mukherjee et al. studied B-Chronic Lymphocytic Leukemia (CLL) which is characterized by 
apoptosis resistance. They found induction of significantly more apoptosis in CLL B cells by co-
culture with an anti-VEGF antibody. To increase the efficacy of these agents in CLL therapy they 
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focused on the use of AuNPs, by attaching VEGF antibody to the nanoparticle’s surface. The 
AuNPVEGF antibody treated cells showed significant down regulation of anti-apoptotic proteins 
(Mukherjee et al., 2007).   
In cancer research, colloidal gold can be used to target tumors and provide detection using SERS 
(Surface Enhanced Raman Spectroscopy) in vivo. These AuNPs are surrounded with Raman 
reporters which provide light emission that is over 200 times brighter than quantum dots (Cai et al., 
2008;Kneipp et al., 2006). It was found that the Raman reporters were stabilized when the 
nanoparticles were encapsulated with a thiol-modified polyethylene glycol coat and gave large 
optical enhancements. This allows for compatibility and circulation in vivo. When conjugated to 
tumor-targeting ligands, these conjugated SERS nanoparticles were able to target tumor markers 
such as epidermal growth factor receptor (EGFR), which is sometimes overexpressed in cells of 
certain cancer types, (El-Sayed et al., 2006;El-Sayed et al., 2005a) and then detect the location of the 
tumor on human cancer cells and in xenograft tumor models (Qian et al., 2008a). Qian et al. 
described biocompatible and nontoxic nanoparticles for in vivo tumor targeting and detection based 
on pegylated gold nanoparticles and surface-enhanced Raman scattering. These conjugated 
nanoparticles were able to target tumor biomarkers such as epidermal growth factor receptors on 
human cancer cells and in xenograft tumor models (Qian et al., 2008a). 
Although cancer therapies are improving, some formulations are not reaching with high efficiency 
tumor cells or tissues, and countless doubts remains over the efficacy of those that do. To efficiently 
target a cancer cell, either a circulation cell or a cell from the primary tumor or one hidden within a 
population of normal cells, represents an exceptional challenge. In fact, there are a lot of limitations 
for tumor targeting as some nanocarriers can also target normal proteins which are not exclusively 
expressed by the cancer cell. Targeting specific cells may be completely different to target the organ. 
The most important aspects that the researchers need to take into account are the specificity of the 
nanoparticle to the target molecules, as well as toxicological and immunological effects (Schroeder 
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et al., 2012). For example, the combination of small size nanoparticles with their special thermal, 
imaging, drug/gene carrier, or optical characteristics with the specific and selective recognition 
abilities of antibodies will definitely produce a hybrid product that shows versatility and specificity. 
Actually, Conde et al reported the evaluation of the inflammatory response and therapeutic 
siRNA silencing via RGD-nanoparticles in a lung cancer mouse model (Conde et al., 2013c). This 
study reported the use of siRNA/RGD gold nanoparticles capable of targeting tumor cells in two 
lung cancer xenograft mouse models, resulting in successful and significant c-Myc oncogene 
downregulation followed by tumor growth inhibition and prolonged survival of the animals. This 
delivery system can achieve translocation of siRNA duplexes directly into the tumour cell cytoplasm 
and accomplish successful silencing of an oncogene expression. Actually, RGD/siRNA-AuNPs can 
target preferentially and be taken up by tumor cells via integrin αvβ3-receptor-mediated endocytosis 
with no cytotoxicity, showing that can accumulate in tumor tissues overexpressing αvβ3 integrins 
and selectively delivered c-Myc siRNA to suppress tumor growth and angiogenesis (Conde et al., 
2013c). 
Therefore, multifunctional nanocarriers have the potential to join numerous therapeutic functions 
into a single platform, by targeting specific tumor cells, tissues and organs. 
 
2.3. Drug delivery 
The vast majority of FDA approved used drugs exhibit a short half-life in the blood stream and a 
high overall clearance rate. In fact, the major obstacles/limitations in drug delivery are: cytoplasmic 
and systemically delivery of the drug, renal clearance, target site accumulation after administration 
and heterogeneous vascular perfusion and diffusion. Actually, these small drug molecules usuaaly 
diffuse rapidly into healthy tissues and are dispersed consistently within the body. As a consequence, 
just a small amount of the drug can reach the target site, which often leads to side effects. These 
obstacles usually occur with drugs that exhibit a narrow therapeutic index, such as anticancer 
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biomolecules, immunosuppressive agents, as well as antirheumatic medicines. Poor drug delivery 
and accumulation at the target site frequently leads to significant limitations, such as multi-drug 
resistance, which leads many cancers to develop severe resistance to chemotherapy drugs (Ehdaie, 
2007). 
Nanocarriers can be used to optimize the biodistribution of drugs to diseased organs, tissues or cells, 
in order to improve and target drug delivery (Han et al., 2007b).  
It is important to realize that the nanoparticle-mediated drug delivery is feasible only if the drug 
distribution is otherwise inadequate. These cases include drug targeting of difficult, unstable 
molecules (proteins, siRNA, DNA), delivery to the difficult sites (brain, retina, tumors, intracellular 
organelles) and drugs with serious side effects (e.g. anti-cancer agents). The performance of the 
nanoparticles depends on the size and surface functionalities in the particles. Also, the drug release 
and particle disintegration can vary depending on the system (eg. biodegradable polymers sensitive 
to pH). An optimal nanodrug delivery system ensures that the active drug is available at the site of 
action for the correct time and duration, and their concentration should be above the minimal 
effective concentration (MEC) and below the minimal toxic concentration (MTC) (Han et al., 
2007a;Langer, 2000).  
AuNPs are also being investigated as vehicles for drug delivery such as paclitaxel (Gibson et al., 
2007). Gibson et al. describe the first example of 2 nm AuNPs covalently functionalized with the 
chemotherapeutic drug paclitaxel. The administrations of hydrophobic drugs require molecular 
encapsulation and it is found that nanosized particles are particularly efficient in evading the 
reticuloendothelial system. This approach gives a rare opportunity to prepare hybrid particles with a 
well-defined amount of drug and offers a new alternative for the design of nanosized drug-delivery 
systems (Kim et al., 2009a;Hwu et al., 2009;Gibson et al., 2007) (see Figure 4) 
Nanotechnology has provided for novel and powerful systems that may be used treatment of human 
diseases. However the majority of products, reagents and drugs being used for the development of 
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these nanoscale systems have to be approved by the main supervising agencies, such as the FDA and 
EMA (Baptista, 2009).  
Thus far, some limitations for the correct design and application of nanoparticles, such as 
pharmacokinetics, biodistribution, and side effects of the nanotherapy; safety profile of nanoparticles 
before and after conjugation and  toxicity, needs to be clarified to validate efficient clinical appliance 
(Baptista, 2009). 
 
3. NanoToxicity 
The AuNPs have a proclivity in vivo and in vitro to bioaccumulate within various types of cells with 
a special affinity for macrophage-type cells (both histiocytes and blood phagocytic cells), and 
reticuloendothelial cells throughout the body). They also produce varying degrees of 
bioaccumulation in such tissues as lymph nodes, bone marrow, spleen, adrenals, liver and kidneys 
(Lasagna-Reeves et al., 2010;Chen et al., 2009;Dobrovolskaia et al., 2008).  
Research shows that nanoparticles can stimulate and/or suppress the immune responses, and that 
their compatibility with the immune system is largely determined by their surface chemistry. In fact, 
is well known the influence of size, solubility and surface modification on the biocompatibility of 
nanoparticles and their use in biological applications (Dobrovolskaia and McNeil, 2007) (see Figure 
5). 
AuNPs are generally considered to be benign. However, the size similarity of AuNPs to biological 
matters could provide “camouflage” to cellular barriers, leading to undesired cellular entry which 
might be detrimental to normal cellular function (Connor et al., 2005). 
Pan and colleagues recently conducted a systematic investigation of the size-dependent cytotoxicity 
of AuNPs against four cell lines (Pan et al., 2007). They found that AuNPs 1 to 2 nm in size 
displayed cell-type dependent cyotoxicity with high micromolar IC50s. In contrast, AuNPs 15 nm in 
size were nontoxic to cells at concentrations 60-fold higher than the IC50 of the smaller AuNPs. 
27 
 
These results seemed to confirm size dependent toxicity of AuNPs (Kim et al., 2009a;Visaria et al., 
2006;Paciotti et al., 2004;El-Sayed et al., 2005b;Huang et al., 2008), an inference that has hitherto 
been somewhat ambivalent. On the other hand, found that the presence of sodium citrate residues on 
AuNPs impaired the viability in the alveolar type-II cell lines A549 and NCIH441. Interestingly, the 
presence of an excess of sodium citrate on the surface of NPs not only reduced the in vitro viability 
of A549 and NCIH441cell lines, but also affected cellular proliferation and increased the release of 
lactate dehydrogenase (marker for apoptotic cell degradation) (Uboldi et al., 2009).  
Although AuNPs are generally considered as highly biocompatible, previous in vitro studies have 
also shown that cytotoxicity of AuNPs in certain human epithelial cells was observed (Freese et al., 
2012;Rothen-Rutishauser et al., 2007). 
Now the most urgent questions rise up. Are the gold nanoparticles cytotoxic or biocompatible? And 
how can the gold nanoparticles be design to avoid these effects? 
There does not seem to have a simple answer. Even though there is not any general mechanism for 
making nanoparticles universally ‘non-toxic’ to all living cells and all organisms, there are important 
findings that can be applied for increasing nanoparticle biocompatibility and reducing cytotoxic 
interactions in vivo and in vitro.  
Using the lowest nanoparticle dose to get the desired response for the shortest period of time, in 
general, seems to promote biocompatibility as well as coating a nanoparticle if the outer coating 
completely covers the nanoparticle reactive surface (a non-continuous covering, the presence of 
cracks, roughness or interruptions could lead to complement or antibody attachment, or dissolution 
of the coating by cell digestion), and cannot be removed and utilized by the living cell (Bellucci, 
2009).  
It is essential to test nanoparticle/biological interactions experimentally and modify the nanoparticles 
for best biocompatibility with the cell in order to eliminate some obstacle, like the peroxidation of 
membrane lipids, the generation of reactive oxygen species, the acute and chronic release of pro-
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inflammatory factors, modification in genetic cellular function, and the possibility of nanoparticles 
becoming inactive/unavailable during filtration or passage through pores and fenestrations (Sun et 
al., 2005) due to size, inflexibility of the nanoparticle core, or protein adsorption and agglomeration 
(Bellucci, 2009). 
When interpreting nanoparticle interactions with cells and organisms, it is important to remember 
that living systems may appear normal and be capable of growth and function, but they may be 
genetically altered in subtle ways following nanoparticle exposure, which can produce serious 
consequences at some time in the distant future. Conversely, other cells that seem to be damaged 
may, in time, recover from nanoparticle exposure and function normally in the absence of the 
nanoparticles (Bellucci, 2009).  
In conclusion, the only weapon that we have to insure that these new materials are well designed and 
safely used is to question and test each new nanoparticle to make sure that it has been designed for 
safety (with maximum biocompatibility) during handling, use and disposal. Evaluating the 
biocompatibility of nanomaterials is imperative. In fact, it is important to carefully characterize the 
biocompatibility and safety of the nanomaterials if they are to be used for medical purposes. Despite 
the major scientific advances made in the field of molecular and cell biology and biotechnology, the 
basic concepts of regulatory toxicology have hardly changed over the past decades (Dobrovolskaia 
and McNeil, 2007). Actually, the vast majority of studies report the biocompatibility of 
nanomaterials only trough the study of cell viability. Almost no importance is given when testing 
nanomaterials in the detection of genetic damages (DNA strand breaks and the formation of nuclear 
abnormalities), or in identifying protein markers of toxicity, or measuring the level of oxidative 
stress. For example, when using gene silencing technologies, the function of specific genes and 
proteins in toxicity pathways could be identified, once DNA-damage response (DNA repair, cell-
cycle regulation and apoptosis) encompasses gene-expression regulation at the transcriptional and 
post-translational levels.  
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In fact, Conde et al. reported a gold-nanobeacon system (Conde et al., 2013b) used for gene therapy 
that was extensively evaluated for the genotoxic, cytotoxic and proteomic effects after incubation in 
cancer cells (Conde et al., 2013a). The exposure was evaluated by two-dimensional protein 
electrophoresis followed by mass spectrometry to perform a proteomic profile and MTT assay, 
glutathione-S-transferase assay, micronucleus test and comet assay to assess the genotoxicity. An 
assessment of genome-related toxicity revealed no significant DNA damage increase, as well as no 
potential mutagenic or clastogenic consequences to the cell (Conde et al., 2013a). 
 
 
4. Conclusions and Future perspectives 
Over the last decade, thousands of different gold nanocarriers were developed and published. Almost 
20% of these papers were published in 2010 alone. It is indisputable that the use of gold nanocarriers 
has been gaining momentum as vectors for therapy and diagnostic strategies, combining the AuNPs’ 
ease of functionalization with numerous biomolecules, high loading capacity and fast uptake by 
target cells. 
Here, we have reviewed part of this exciting progress and research advances within the context of 
multifunctional gold nanocarriers for cancer theranostics. Despite the significant efforts towards the 
use of gold nanocarriers in biologically relevant research, more in vivo studies are needed to assess 
the applicability of these materials as delivery agents. In fact, only a few went through feasible 
clinical trials. Nanoparticles have to serve as the norm rather than an exception in the future 
conventional cancer treatments. Future in vivo work will need to carefully consider the correct choice 
of chemical modifications to incorporate into the multifunctional gold nanocarriers to avoid 
activation off-target, side effects and toxicity. Moreover the majority of studies on nanomaterials do 
not consider the final application to guide the design and functionalization of NP. Instead, the focus 
is predominantly on engineering materials with specific physical or chemical properties.  
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Although great effort has been applied to the detection of microorganisms and/or virus using gold 
biosensors only a few were used for the detection of chronic diseases, such as cancer. The lack of 
specific and unique DNA/RNA markers and the complexity of the intricate regulation pathways have 
made the development of probes rather difficult. Particularly in cancer, future trends need to be 
focused on the detection of microRNAs and circulating DNA biomarkers or the recognition of 
circulating tumor cells followed by a detection step. Since most of the nanodiagnostic systems report 
DNA sequence analysis/detection, the great majority ignored the important genomic and 
transcriptomic information when detecting messengerRNA and microRNAs, which are considered to 
be excellent biomarkers for the early diagnosis of cancer.  
To improve medicine, scientific discoveries must be translated into clinical applications. Such 
discoveries typically begin at “the bench” with basic/fundamental research in which scientists study 
disease at a molecular or cellular level then progress to the clinical level, which is the patient's 
“bedside”. Scientists and clinicians are increasingly aware that this bench-to-bedside approach to 
translational research is really a two-way interaction. However, an additional effort should appear 
towards the development of new clinical strategies. 
Moreover, the systems discussed here are each of them unique in many aspects. Some of the 
nanoformulations have very well defined structures, whereas some are highly heterogeneous. Some 
have a wide range of size, charge and surface. This raises the important question about the reliability 
of their production protocols. The great majority of the nanosystems described here presents or will 
present additional challenges in the scale-up of the manufacturing process. Besides, central concerns 
about nanoparticle’s biodistribution and the proper considerations of safety for the patients. 
Therefore, the establishment of safe regulatory approval nanoformulations turns to be essential.  
For that reason, it is imperative to learn how advances in nanosystem’s capabilities are being used to 
identify new diagnostic and therapy tools driving the development of personalized medicine in 
oncology; discover how integrating cancer research and nanotechnology modeling can help patient 
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diagnosis and treatment; recognize how to translate nanotheranostics data into an actionable clinical 
strategy; discuss with industry leaders how nanotheranostics is evolving and what the impact is on 
current research efforts; and last but not least, learn what approaches are proving fruitful in turning 
promising clinical data into treatment realities. 
Although all studies described here provide a baseline level of data in support of the effectiveness 
and safety of nanomaterials, we wonder how useful the data generated will be in successfully 
predicting and preventing scientists from jeopardizing the safety of the future patients? 
With chemists, biologists and materials scientists working together with clinicians and engineers, but 
especially with “translational innovators” new solutions to crucial nanobiomedical problems will 
hopefully be found. 
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Figure legends 
 
Figure 1. Nanocarriers for Cancer Theranostics. Nanoparticles-based strategies can be used for 
biosensing using plasmonic nanosensors for colorimetric assays and bio-bar codes for protein 
detection or intense labels for immunoassays. Moreover, the use of metal surfaces to enhance the 
Raman scattering signal of target molecules may be used for cancer diagnostics. Engineered 
nanocarriers can also act as therapeutic agents via gene silencing and drug delivery systems. Some 
nanocarriers can be attached to specific targets for selective damage to cancer cells through tumor 
targeting approaches. 
 
Figure 2. The colorimetric assay. (A) Oligonucleotide probe and target sequences designed for 
BCR-ABL b3a2 (e14a2) junction and for BCR and ABL genes. Complementary and non-
complementary target sequences were used to study the level of specific interaction between the 
target and the Au-nanoprobes. BCR-ABL fusion positive (100% complementary); BCR and ABL 
gene sequences were used as controls (50% non-complementary); and a completely unrelated 
sequence (100% non-complementary) was used as negative control. (B) The assay is based on the 
increased stability of the Au-nanoprobes upon hybridization with the complementary target in 
solution, while non-hybridized Au-nanoprobes easily aggregate once the solution’s ionic strength is 
increased. The absence of full complementarity is revealed by a change of color from red to blue due 
to A-nanoprobe aggregation which is corroborated by naked eye and UV/vis spectroscopy. BCR-
ABL Positive: sample in the presence of complementary target (solution remains red); BCR-ABL 
Negative: sample in the presence of non-complementary target (solution turns blue). (C) 
Spectrophotometry relative to the detection of synthetic BCR-ABL oligonucleotide target. 
Oligonucleotides with BCR or ABL sequence only (showing 50% complementarity) were used as 
controls and an unrelated target (showing 100% non-complementarity to the Au-nanoprobe) as 
45 
 
negative control. (D) Detection of BCR-ABL in total RNA from K562 cell line, HL-60 cell line and 
human PBMC (harboring 50% complementary targets to the nanoprobe) and S. cerevisiae cells 
(100% non-complementary). Nanoprobe aggregation as measured by ratio of area under the curve 
AUC500 nm-560 nm/AUC570 nm-630 nm. The dashed line represents the threshold of 1 considered 
for discrimination between Positive and Negative. 
 
Figure 3. Disproportional level between nanoparticle production and their translation into 
clinics. Thousands of systems were published describing different synthesis, biofunctionalization and 
characterization methods that will most likely revolutionize our understanding of chemical and 
biological mechanisms and push forward efficient diagnostics and therapeutic platforms. 
Nevertheless, very few were produced to improve a bench-to-bedside approach to translational 
research. Outcomes like this must be followed by extensive laboratory work, which results in 
improved screening procedures and a new therapy of great potential, although the final product 
should always be part of a two way interaction between laboratory scientists and clinicians. 
 
Figure 4. Drug delivery. Entrapment of hydrophobic drugs in nanoparticle monolayers with 
efficient release into cancer cells (A) Delivery of payload to cell through monolayer-membrane 
interactions. (B) Structure of particles and guest compounds: Bodipy, TAF, and LAP, the number of 
encapsulated guests per particle, and log P of the guests. (C) Release of Bodipy from AuNPZwit 
Bodipy in DCM-aqueous solution two-phase systems (λex) 499 nm, λem) 517 nm). (D) PL intensity 
of AuNPZwit-Bodipy in cell culture medium and 100% serum, indicating little or no release relative 
to AuNPZwit-Bodipy in PBS after NaCN induced release of guest molecules (λex) 499 nm, λem) 
510 nm). Reproduced with permission [ Kim et al., 2009a]. Copyright 2013, American Chemical 
Society. 
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Figure 5. NanoToxicity: Causes and Effects. Nanoparticles biocompatibility/effects and their use 
in biological applications can be influenced by size, shape, solubility, composition and surface 
charge and modification/chemistry. 
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